01110 KINGWORLD
- 0.510
- -0.030-5.56%
KINGWORLD News
Kingworld Medicines Posts 68% Jump in 2023 Profit
Kingworld Medicines Group (HKG:1110) reported a 67.5% increase in profit attributable to owners for the year ended Dec. 31, 2023, to 38.1 million yuan, up from 22.7 million yuan in the previous year,
金活醫藥集團：年報 2023
Jinhuo Pharmaceutical Group (01110) will pay a final dividend of HK$0.0338 per share on June 28
According to the Zhitong Finance App, Jinhuo Pharmaceutical Group (01110) announced that the company will pay a final dividend of HK$0.0338 per share on June 28, 2024.
Jinhuo Pharmaceutical (1110.HK): Profit attributable to owners increased 67.5% year-on-year, and diversified breakthroughs showed new vitality
In 2023, in an environment of many uncertainties, many industries will enter a critical period of transformation. Faced with the ever-changing market environment and demands, different pharmaceutical companies also gave different answers. Among them, Jinhuo Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Jinhuo Pharmaceutical”), which has been established for more than 20 years, has been successfully operating many well-known pharmaceutical products, including Kyoto Nianjian Honey Refined Kawakai Loquat Cream, which can be called “the light of domestic products.” In recent years, Jinhuo Pharmaceutical has also relied on its rich marketing strategies to meet market demand and transform it into its own growth vitality, achieve multiple breakthroughs, and lead the company to a good start
Jinhuo Pharmaceutical Group (01110) will pay a final dividend of HK$0.0338 per share on June 30
Jinhuo Pharmaceutical Group (01110) announced that the company will pay a final dividend per share on June 30, 2024...
Jinhuo Pharmaceutical Group (01110.HK): Net profit increased sharply by 67.5% year-on-year in 2023, and proposed final interest of HK3.38 HK cents per share
On March 26, Ge Longhui Pharmaceutical Group (01110.HK) announced that for the year ended December 31, 2023, earnings increased by 12.6% to approximately RMB 1,079 million; profit attributable to company owners increased by 67.5% to approximately RMB 38.96 million, and basic profit per share increased 71.7% to approximately RMB 6.44 percent. The Board recommended a final dividend of HK3.38 cents per share. During the year under review, the increase in the Group's earnings was mainly due to an increase in revenue from Kyoto Ninjian Honey Refined Kawakai Loquat Cream. The main reason for this increase is the prevention and control of the epidemic and changes to the epidemic
Jinhuo Pharmaceutical Group (01110) announced annual results. Profit attributable to shareholders of RMB 38.96 million increased by 67.52% year-on-year
Jinhuo Pharmaceutical Group (01110) announced its annual results for the year ended December 31, 2023. The group period...
KINGWORLD: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Kingworld Medicine Expects Up to 75% Profit Jump in 2023; Shares Up 6%
Kingworld Medicine Group (HKG:1110) expects to book a 65% to 75% increase in attributable profit for the year ended Dec. 31, 2023, compared with an attributable profit of 22.7 million yuan in the year
Jinhuo Pharmaceutical Group (01110.HK) Yingxi: Annual net profit is expected to increase by about 65% to 75%
Gelonghui, March 20, 丨 Jinhuo Pharmaceutical Group (01110.HK) announced that the company expects the group profit attributable to the company owner for the year ended December 31, 2023 to increase the group profit attributable to the company owner by about 65% to 75% by RMB 22.7 million in the previous year. The board of directors believes that the increase in group profit due to the cancellation of control measures against the novel coronavirus (COVID-19) epidemic was mainly due to (i) market recovery this year compared to the previous year due to the cancellation of control measures against the novel coronavirus () epidemic, which led to an increase in revenue from the Chinese distribution business of branded imported pharmaceuticals and health care products by about 10% to 1
Jinhuo Pharmaceutical Group (01110.HK) will hold a board meeting on March 26 to approve the annual results
Gelonghui, March 14, 丨 Jinhuo Pharmaceutical Group (01110.HK) announced that the company will hold a board meeting on March 26, 2024 to review and approve the Group's audited annual results for the year ended December 31, 2023 and the proposed payment of a final dividend (if any), and to deal with any other matters.
KINGWORLD: Interim Report 2023
Following the 'general trend' and striving for the 'small trend', Jinhuo Pharmaceutical (1110.HK) achieved high performance growth
In recent years, as traditional Chinese medicine is being used more and more widely in daily life, consumer awareness and approval of traditional Chinese medicine has reached a new level, and the performance of the traditional Chinese medicine sector has ushered in continuous growth. In the first half of this year, the overall performance of Chinese pharmaceutical companies was still a bright spot in the pharmaceutical sector. According to incomplete statistics, at least 70% of the 58 Chinese medicine companies that have now disclosed their semi-annual results have achieved performance growth. Among them, Jinhuo Pharmaceutical's performance, which has been working in the field of traditional Chinese medicine for many years, has increased significantly. Financial reports show that in the first half of this year, Jinhuo Pharmaceutical's revenue reached 553 million yuan, an increase of 31.8% over the previous year; profit for the period was 0.4
Jinhuo Pharmaceutical announced its interim results. Profit attributable to the company's owners increased by 55.8% year-on-year; domestic distribution business recovered at an accelerated pace, and core product performance was impressive
On August 28, Jinhuo Pharmaceutical Group Co., Ltd. (“Jinhuo Pharmaceutical” or “Group”, stock code: 01110.HK), a leading pharmaceutical and health distribution company, was pleased to announce its unaudited interim results for the six months ended June 30, 2023 (“reporting period” or “first half year”). During the reporting period, benefiting from the overall recovery in China's economy and consumer business, the Group recorded turnover of about RMB 553 million, up 31.8% from the same period last year; gross profit increased 15.7% to approximately RMB 155 million; profit for the period was approximately RMB 48 million, up 35 million from the same period last year.
KINGWORLD: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical
Kingworld Medicines Group (HKG:1110) subsidiary Kingworld Medicines Health Management purchased an additional 1,007,500 shares in Japan-based Taiko Pharmaceutical (TYO:4574) at 338.58 yen per share, a
Jinhuo Pharmaceutical Group (01110.HK): Further subscription for shares in Taiko Pharmaceutical
On August 16, 2023, Goldwell Pharmaceutical Group (01110.HK) issued an announcement. On August 15, 2023, Jinhuo Pharmaceutical, a wholly-owned subsidiary of the company, placed an order with the distribution agent. Based on this, Jinhuo Pharmaceutical agreed to subscribe for an additional 1.075 million Taiko shares at a cost of 338.58 yen (equivalent to about HK$18.35) per share of Taiko Shares (accounting for about 2.08% of Taiko Pharmaceutical's issued share capital as of the date of this announcement, excluding Taiko Pharmaceutical After completion, according to the subscription details
KINGWORLD: NOTICE OF BOARD MEETING
Jinhuo Pharmaceutical Group's Fa Yingxi expects medium-term profit to increase by about 35% to 40%
Jinhuo Pharmaceutical Group (01110) announced that the group's profit for the six months ending June 30, 2023 is expected to increase by about 35% to 40% compared to the group profit of RMB 35.1 million in the first half of 2022.
Jinhuo Pharmaceutical Group (01110.HK) Yingxi: Mid-term profit is expected to increase by about 35% to 40%
On August 2, GLONGHUO PHARMACEUTICAL GROUP (01110.HK) announced that the company expects the profit for the six months ending June 30, 2023 to increase by about 35% to 40% over the profit of RMB 35.1 million in the same period last year. The Board of Directors believes that the increase in the Group's profit was mainly due to the cancellation of control measures against the novel coronavirus (COVID-19) epidemic, which caused the market to recover compared to the previous period, resulting in (i) revenue and gross profit from the distribution business of branded imported pharmaceuticals and health care products in China increased by about 30% to 35% and 15% to 20%, respectively; and (ii) it should account for one company
Analysis
Price Target
No Data
